[{"address1": "6200 Lookout Road", "city": "Boulder", "state": "CO", "zip": "80301", "country": "United States", "phone": "720 647 8519", "website": "https://www.enliventherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a CNS penetrant and irreversible HER2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 driven cancers and solid tumors. The company is headquartered in Boulder, Colorado.", "fullTimeEmployees": 65, "companyOfficers": [{"maxAge": 1, "name": "Mr. Samuel S. Kintz M.B.A.", "age": 38, "title": "Co-Founder & Head of Pipeline", "yearBorn": 1987, "fiscalYear": 2024, "totalPay": 973800, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Joseph P. Lyssikatos Ph.D.", "age": 60, "title": "Co-Founder & Chief Scientific Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 709400, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Helen Louise Collins M.D.", "age": 62, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 746400, "exercisedValue": 0, "unexercisedValue": 4612248}, {"maxAge": 1, "name": "Mr. Richard A. Fair", "age": 56, "title": "CEO, President & Director", "yearBorn": 1969, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Anish  Patel Pharm.D.", "age": 45, "title": "Co-Founder & COO", "yearBorn": 1980, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Benjamin  Hohl", "age": 36, "title": "CFO & Head of Corporate Development", "yearBorn": 1989, "fiscalYear": 2024, "totalPay": 488500, "exercisedValue": 0, "unexercisedValue": 1212737}, {"maxAge": 1, "name": "Dr. Galya D. Blachman Esq., Ph.D.", "age": 48, "title": "Chief Legal Officer & Head of Business Development", "yearBorn": 1977, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 7, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1769904000, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 26.16, "open": 25.94, "dayLow": 25.35, "dayHigh": 26.355, "regularMarketPreviousClose": 26.16, "regularMarketOpen": 25.94, "regularMarketDayLow": 25.35, "regularMarketDayHigh": 26.355, "payoutRatio": 0.0, "beta": 1.143, "forwardPE": -10.978904, "volume": 572721, "regularMarketVolume": 572721, "averageVolume": 1038055, "averageVolume10days": 700120, "averageDailyVolume10Day": 700120, "bid": 25.93, "ask": 26.17, "bidSize": 2, "askSize": 1, "marketCap": 1544217216, "fiftyTwoWeekLow": 13.3, "fiftyTwoWeekHigh": 30.22, "allTimeHigh": 250.84, "allTimeLow": 3.896, "fiftyDayAverage": 22.5263, "twoHundredDayAverage": 20.800276, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 1067142208, "profitMargins": 0.0, "floatShares": 33700967, "sharesOutstanding": 59347317, "sharesShort": 7870182, "sharesShortPriorMonth": 8312949, "sharesShortPreviousMonthDate": 1767139200, "dateShortInterest": 1769731200, "sharesPercentSharesOut": 0.13260001, "heldPercentInsiders": 0.08271, "heldPercentInstitutions": 1.06848, "shortRatio": 5.2, "shortPercentOfFloat": 0.1887, "impliedSharesOutstanding": 59347317, "bookValue": 8.034, "priceToBook": 3.2387352, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -97207000, "trailingEps": -1.81, "forwardEps": -2.37, "enterpriseToEbitda": -9.53, "52WeekChange": 0.22529268, "SandP52WeekChange": 0.14684999, "quoteType": "EQUITY", "currentPrice": 26.02, "targetHighPrice": 52.0, "targetLowPrice": 33.0, "targetMeanPrice": 41.375, "targetMedianPrice": 40.0, "recommendationKey": "none", "numberOfAnalystOpinions": 8, "totalCash": 477564992, "totalCashPerShare": 8.047, "ebitda": -111972000, "totalDebt": 490000, "quickRatio": 32.598, "currentRatio": 32.948, "debtToEquity": 0.103, "returnOnAssets": -0.17623, "returnOnEquity": -0.25429, "freeCashflow": -45616124, "operatingCashflow": -71666000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "ELVN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "regularMarketChangePercent": -0.535166, "regularMarketPrice": 26.02, "exchange": "NMS", "messageBoardId": "finmb_693128628", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "longName": "Enliven Therapeutics, Inc.", "shortName": "Enliven Therapeutics, Inc.", "corporateActions": [], "postMarketTime": 1771625376, "regularMarketTime": 1771621202, "fiftyTwoWeekChangePercent": 22.529268, "earningsTimestampStart": 1773349200, "earningsTimestampEnd": 1773349200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -1.81, "epsForward": -2.37, "epsCurrentYear": -1.8, "priceEpsCurrentYear": -14.455556, "fiftyDayAverageChange": 3.4937, "fiftyDayAverageChangePercent": 0.15509427, "twoHundredDayAverageChange": 5.2197247, "twoHundredDayAverageChangePercent": 0.25094497, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "firstTradeDateMilliseconds": 1584019800000, "postMarketChangePercent": 0.0, "postMarketPrice": 26.02, "postMarketChange": 0.0, "regularMarketChange": -0.139999, "regularMarketDayRange": "25.35 - 26.355", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1038055, "fiftyTwoWeekLowChange": 12.72, "fiftyTwoWeekLowChangePercent": 0.956391, "fiftyTwoWeekRange": "13.3 - 30.22", "fiftyTwoWeekHighChange": -4.199999, "fiftyTwoWeekHighChangePercent": -0.13898078, "hasPrePostMarketData": true, "marketState": "CLOSED", "displayName": "Enliven Therapeutics", "trailingPegRatio": null, "__fetch_time": "2026-02-21"}]